The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Targeting NADPH oxidases in vascular pharmacology
Open accessAbstract
Oxidative stress is a molecular dysregulation in reactive oxygen species (ROS) metabolism, which plays a key role in the pathogenesis of atherosclerosis, vascular inflammation and endothelial dysfunction. It is characterized by a loss of nitric oxide (NO) bioavailability. Large clinical trials such as HOPE and HPS have not shown a clinical benefit of antioxidant vitamin C or vitamin E treatment, putting into question the role of oxidative stress in cardiovascular disease. A change in the understanding of the molecular nature of oxidative stress has been driven by the results of these trials. Oxidative stress is no longer perceived as a simple imbalance between the production and scavenging of ROS, but as a dysfunction of enzymes involved in ROS production. NADPH oxidases are at the center of these events, underlying the dysfunction of other oxidases including eNOS uncoupling, xanthine oxidase and mitochondrial dysfunction. Thus NADPH oxidases are important therapeutic targets. Indeed, HMG-CoA reductase inhibitors (statins) as well as drugs interfering with the renin-angiotensin-aldosterone system inhibit NADPH oxidase activation and expression. Angiotensin-converting enzyme (ACE) inhibitors, AT1 receptor antagonists (sartans) and aliskiren, as well as spironolactone or eplerenone, have been discussed. Molecular aspects of NADPH oxidase regulation must be considered, while thinking about novel pharmacological targeting of this family of enzymes consisting of several homologs Nox1, Nox2, Nox3, Nox4 and Nox5 in humans. In order to properly design trials of antioxidant therapies, we must develop reliable techniques for the assessment of local and systemic oxidative stress. Classical antioxidants could be combined with novel oxidase inhibitors. In this review, we discuss NADPH oxidase inhibitors such as VAS2870, VAS3947, GK-136901, S17834 or plumbagin. Therefore, our efforts must focus on generating small molecular weight inhibitors of NADPH oxidases, allowing the selective inhibition of dysfunctional NADPH oxidase homologs. This appears to be the most reasonable approach, potentially much more efficient than non-selective scavenging of all ROS by the administration of antioxidants.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The NOX Family of ROS-Generating NADPH Oxidases: Physiology and Pathophysiology
Bedard, K., & Krause, K.-H. (2007) · Physiological Reviews · doi:10.1152/physrev.00044.2005 · Cited by 6,989
Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress
Cai, H., & Harrison, D. G. (2000) · Circulation Research · doi:10.1161/01.res.87.10.840 · Cited by 3,839
Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease
Omenn, G. S., Goodman, G. E., Thornquist, M. D., Balmes, J., Cullen, M. R., Glass, A., Keogh, J. P., Meyskens, F. L., Valanis, B., Williams, J. H., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199605023341802 · Cited by 3,638
Meta-Analysis: High-Dosage Vitamin E Supplementation May Increase All-Cause Mortality
Miller, E. R., Pastor-Barriuso, R., Dalal, D., Riemersma, R. A., Appel, L. J., & Guallar, E. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-1-200501040-00110 · Cited by 2,577
Bjelakovic, G., Nikolova, D., Gluud, L. L., Simonetti, R. G., & Gluud, C. (2007) · JAMA · doi:10.1001/jama.297.8.842 · Cited by 2,275
Stephens, N. G., Parsons, A., Brown, M. J., Schofield, P. M., Kelly, F., Cheeseman, K., & Mitchinson, M. (1996) · The Lancet · doi:10.1016/s0140-6736(96)90866-1 · Cited by 2,148
Brown, B. G., Zhao, X.-Q., Chait, A., Fisher, L. D., Cheung, M. C., Morse, J. S., Dowdy, A. A., Marino, E. K., Bolson, E. L., Alaupovic, P., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011090 · Cited by 1,979
Vitamin E Supplementation and Cardiovascular Events in High-Risk Patients
(2000) · New England Journal of Medicine · doi:10.1056/nejm200001203420302 · Cited by 1,957
Role of the T cell in the genesis of angiotensin II–induced hypertension and vascular dysfunction
Guzik, T. J., Hoch, N. E., Brown, K. A., McCann, L. A., Rahman, A., Dikalov, S., Goronzy, J., Weyand, C., & Harrison, D. G. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20070657 · Cited by 1,736
Self-citationJones, D. P. (2006) · Antioxidants & Redox Signaling · doi:10.1089/ars.2006.8.1865 · Cited by 1,726
Landmesser, U., Dikalov, S., Price, S. R., McCann, L., Fukai, T., Holland, S. M., Mitch, W. E., & Harrison, D. G. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200314172 · Cited by 1,660
Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia
Després, J.-P., Golay, A., & Sjöström, L. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044537 · Cited by 1,392 · cited 2×
“Indeed, CB1 blockade has been shown to reduce body weight, blood pressure and insulin resistance, improve lipid levels (Despres et al., 2005; Van Gaal et al., 2008b), limit hepatic steatosis (Tam et al.”
Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials
Christensen, R., Kristensen, P. K., Bartels, E. M., Bliddal, H., & Astrup, A. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61721-8 · Cited by 1,097 · cited 2×
“Unfortunately, adverse psychiatric effects such as depressed mood disorders and anxiety (Christensen et al., 2007), irritability and aggression (Rucker et al.”
Vitamins C and E: Beneficial effects from a mechanistic perspective
Traber, M. G., & Stevens, J. F. (2011) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2011.05.017 · Cited by 1,076
Combating oxidative stress in vascular disease: NADPH oxidases as therapeutic targets
Drummond, G. R., Selemidis, S., Griendling, K. K., & Sobey, C. G. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3403 · Cited by 899
Kregel, K. C., & Zhang, H. J. (2007) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00327.2006 · Cited by 883
Doughan, A. K., Harrison, D. G., & Dikalov, S. I. (2008) · Circulation Research · doi:10.1161/circresaha.107.162800 · Cited by 710
A Ca2+-activated NADPH Oxidase in Testis, Spleen, and Lymph Nodes
Bánfi, B., Molnár, G., Maturana, A., Steger, K., Hegedûs, B., Demaurex, N., & Krause, K.-H. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m103034200 · Cited by 622
Probucol and Multivitamins in the Prevention of Restenosis after Coronary Angioplasty
Tardif, J.-C., Côté, G., Lespérance, J., Bourassa, M., Lambert, J., Doucet, S., Bilodeau, L., Nattel, S., & de Guise, P. (1997) · New England Journal of Medicine · doi:10.1056/nejm199708073370601 · Cited by 565
Ambasta, R. K., Kumar, P., Griendling, K. K., Schmidt, H. H. H. W., Busse, R., & Brandes, R. P. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m406486200 · Cited by 541
Is oxidative stress a therapeutic target in cardiovascular disease?
Münzel, T., Gori, T., Bruno, R. M., & Taddei, S. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehq396 · Cited by 470
Nox3, a superoxide-generating nadph oxidase of the inner ear
Bánfi, B., Malgrange, B., Knisz, J., Steger, K., Dubois-Dauphin, M., & Krause, K.-H. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m403046200 · Cited by 467
T cells express a phagocyte-type NADPH oxidase that is activated after T cell receptor stimulation
Jackson, S. H., Devadas, S., Kwon, J., Pinto, L. A., & Williams, M. S. (2004) · Nature Immunology · doi:10.1038/ni1096 · Cited by 457
Sedeek, M., Callera, G., Montezano, A., Gutsol, A., Heitz, F., Szyndralewiez, C., Page, P., Kennedy, C. R. J., Burns, K. D., Touyz, R. M., et al. (2010) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00028.2010 · Cited by 396
Salonen, J. T., Nyyssönen, K., Salonen, R., Lakka, H. ‐., Kaikkonen, J., Porkkala‐Sarataho, E., Voutilainen, S., Lakka, T. A., Rissanen, T., Leskinen, L., et al. (2000) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.2000.00752.x · Cited by 327
Guzik, T. J., Chen, W., Gongora, M. C., Guzik, B., Lob, H. E., Mangalat, D., Hoch, N., Dikalov, S., Rudzinski, P., Kapelak, B., et al. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.07.063 · Cited by 281
Self-citationCoronary Artery Superoxide Production and Nox Isoform Expression in Human Coronary Artery Disease
Guzik, T. J., Sadowski, J., Guzik, B., Jopek, A., Kapelak, B., Przybyłowski, P., Wierzbicki, K., Korbut, R., Harrison, D. G., & Channon, K. M. (2006) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000196651.64776.51 · Cited by 278
Self-citationTENFREYHAUS, H., HUNTGEBURTH, M., WINGLER, K., SCHNITKER, J., BAUMER, A., VANTLER, M., BEKHITE, M., WARTENBERG, M., SAUER, H., & ROSENKRANZ, S. (2006) · Cardiovascular Research · doi:10.1016/j.cardiores.2006.01.022 · Cited by 259
Comparative pharmacology of chemically distinct nadph oxidase inhibitors
Wind, S., Beuerlein, K., Eucker, T., Müller, H., Scheurer, P., Armitage, M., Ho, H., Schmidt, H., & Wingler, K. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00920.x · Cited by 241
Antoniades, C., Bakogiannis, C., Leeson, P., Guzik, T. J., Zhang, M.-H., Tousoulis, D., Antonopoulos, A. S., Demosthenous, M., Marinou, K., Hale, A., et al. (2011) · Circulation · doi:10.1161/circulationaha.110.985150 · Cited by 219
Self-citationNox1, 2, 4, 5: Counting out oxidative stress
Wingler, K., Hermans, J., Schiffers, P., Moens, A., Paul, M., & Schmidt, H. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01249.x · Cited by 113
Cited by
Endothelial dysfunction — A major mediator of diabetic vascular disease
Sena, C. M., Pereira, A. M., & Seiça, R. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.08.006 · Cited by 797
Oxidative Stress, Inflammation, and Vascular Aging in Hypertension
Guzik, T. J., & Touyz, R. M. (2017) · Hypertension · doi:10.1161/hypertensionaha.117.07802 · Cited by 766
Self-citationCano Sanchez, M., Lancel, S., Boulanger, E., & Neviere, R. (2018) · Antioxidants · doi:10.3390/antiox7080098 · Cited by 574
Rochette, L., Lorin, J., Zeller, M., Guilland, J.-C., Lorgis, L., Cottin, Y., & Vergely, C. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.07.004 · Cited by 456
Angiotensin II and Vascular Injury
Montezano, A. C., Nguyen Dinh Cat, A., Rios, F. J., & Touyz, R. M. (2014) · Current Hypertension Reports · doi:10.1007/s11906-014-0431-2 · Cited by 402
Metadata
- Authors
- Schramm, A., Matusik, P., Osmenda, G., & Guzik, T. J.
- Venue
- Vascular Pharmacology
- Publisher
- Elsevier BV
- Published
- 2012-05
- Volume
- 56
- Issue
- 5-6
- Pages
- 216-231
- ISSN
- 1537-1891 (ISSN-L)
- OpenAlex
- W2079159302
- Cited by
- 228
- References
- 32
- FWCI
- 17.74
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.